Carbonic Anhydrase IX in Renal Cell Carcinoma: Implications for Prognosis, Diagnosis, and Therapy

European Urology

Volumn 58, Issue 1, 2010, Pages 75-83

  Stillebroer, Alexander B ^a   Mulders, Peter F A ^a   Boerman, Otto C ^a   Oyen, Wim J G ^a   Oosterwijk, Egbert ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen; CAIX; Carbonic anhydrase 9; Clear cell renal cell carcinoma; Diagnosis; Prognosis; RCC; Therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBONATE DEHYDRATASE IX; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IODINE 124; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY G250; MONOCLONAL ANTIBODY G250 I 131; MONOCLONAL ANTIBODY G250 IN 111; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; YTTRIUM 90;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL; DENDRITIC CELL; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; FATIGUE; HUMAN; INFORMATION RETRIEVAL; ISOTOPE LABELING; KIDNEY CARCINOMA; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MEDLINE; METASTASIS; NAUSEA; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MUTATION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 77952878558     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.03.015     Document Type: Review

References (74)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 59 (2009) 225-249
2. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
3. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (2009) 3584-3590
4. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., and Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688-696
5. Negrier S., Perol D., Ravaud A., et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110 (2007) 2468-2477
6. Hartmann J.T., Haap M., Kopp H.G., and Lipp H.P. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab 10 (2009) 470-481
7. Heng D.Y., and Choueiri T.K. Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw 7 (2009) 659-665
8. Oosterwijk E., Ruiter D.J., Hoedemaeker P.J., et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38 (1986) 489-494
9. Grabmaier K., Vissers J.L., De Weijert M.C., et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 85 (2000) 865-870
10. Opavsky R., Pastorekova S., Zelnik V., et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 33 (1996) 480-487
11. Supuran C.T. Carbonic anhydrases: catalytic and inhibition mechanisms, distribution and physiological roles. In: Supuran C.T., Scozzafava A., and Conway J. (Eds). Carbonic anhydrase: its inhibitors and activators (2004), CRC Press, Boca Raton, Florida 1-23
12. Bismar T.A., Bianco F.J., Zhang H., et al. Quantification of G250 mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections. Pathology 35 (2003) 513-517
13. Saarnio J., Parkkila S., Parkkila A.K., et al. Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours. J Hepatol 35 (2001) 643-649
14. Thiry A., Dogne J.M., Masereel B., and Supuran C.T. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 27 (2006) 566-573
15. Bartosova M., Parkkila S., Pohlodek K., et al. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol 197 (2002) 314-321
16. Ivanov S., Liao S.Y., Ivanova A., et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158 (2001) 905-919
17. Hynninen P., Vaskivuo L., Saarnio J., et al. Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology 49 (2006) 594-602
18. Kivela A., Parkkila S., Saarnio J., et al. Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. Am J Pathol 156 (2000) 577-584
19. Kivela A.J., Parkkila S., Saarnio J., et al. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem Cell Biol 114 (2000) 197-204
20. Saarnio J., Parkkila S., Parkkila A.K., et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153 (1998) 279-285
21. Leibovich B.C., Sheinin Y., Lohse C.M., et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 25 (2007) 4757-4764
22. Kaluz S., Kaluzova M., Liao S.Y., Lerman M., and Stanbridge E.J. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?. Biochim Biophys Acta 1795 (2009) 162-172
23. Grabmaier K., Weijert M.C.A., Verhaegh G.W., Schalken J.A., and Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 23 (2004) 5624-5631
24. Shin K.H., az-Gonzalez J.A., Russell J., et al. Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther 6 (2007) 70-75
25. Ihnatko R., Kubes M., Takacova M., et al. Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol 29 (2006) 1025-1033
26. Rafajova M., Zatovicova M., Kettmann R., Pastorek J., and Pastorekova S. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol 24 (2004) 995-1004
27. Chiche J., Ilc K., Laferriere J., et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 69 (2009) 358-368
28. Bui M.H., Seligson D., Han K.R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
29. Sandlund J., Oosterwijk E., Grankvist K., Oosterwijk-Wakka J., Ljungberg B., and Rasmuson T. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 100 (2007) 556-560
30. Patard J.J., Fergelot P., Karakiewicz P.I., et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 123 (2008) 395-400
31. de Martino M., Klatte T., Seligson D.B., et al. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol 182 (2009) 728-734
32. Galfano A., Novara G., Iafrate M., et al. Mathematical models for prognostic prediction in patients with renal cell carcinoma. Urol Int 80 (2008) 113-123
33. Kim H.L., Seligson D., Liu X., et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173 (2005) 1496-1501
34. Kim H.L., Seligson D., Liu X., et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10 (2004) 5464-5471
35. Al-Ahmadie H.A., Alden D., Qin L.X., et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol 32 (2008) 377-382
36. Li Y., Wang H., Oosterwijk E., et al. Antibody-specific detection of CAIX in breast and prostate cancers. Biochem Biophys Res Commun 386 (2009) 488-492
37. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11 (2005) 3714-3721
38. McDermott D. The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma (SELECT). http://clinicaltrials.gov/ct2/show/NCT00554515. Accessed March 9, 2010.
39. Klatte T., Zomorodian N., Kabinavar F.F., Belldegrun A., and Pantuck A. Prospective evaluation of carbonic anhydrase IX (CAIX) as a molecular marker in metastatic renal cell carcinoma [abstract]. J Clin Oncol 25 Suppl (2007) 5112
40. Choueiri T.K., Regan M., Oh W., et al. Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy [abstract]. J Clin Oncol 27 Suppl (2009) 16067
41. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
42. Cho D., Signoretti S., Dabora S., et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5 (2007) 379-385
43. Poeppel T.D., Krause B.J., Heusner T.A., Boy C., Bockisch A., and Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol 70 (2009) 382-392
44. Powles T., Murray I., Brock C., Oliver T., and Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 51 (2007) 1511-1521
45. Ak I., and Can C. F-18 FDG PET in detecting renal cell carcinoma. Acta Radiol 46 (2005) 895-899
46. Divgi C.R., Bander N.H., Scott A.M., et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4 (1998) 2729-2739
47. Steffens M.G., Boerman O.C., Oosterwijk-Wakka J.C., et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 15 (1997) 1529-1537
48. Brouwers A.H., Dorr U., Lang O., et al. 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl Med Commun 23 (2002) 229-236
49. Brouwers A.H., Buijs W.C., Oosterwijk E., et al. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res 9 (2003) 3953S-3960S
50. Brouwers A.H., Mulders P.F., De Mulder P.H., et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 23 (2005) 6540-6548
51. Brouwers A.H., Buijs W.C., Mulders P.F., et al. Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res 11 (2005) 7178s-7186s
52. Divgi C.R., Pandit-Taskar N., Jungbluth A.A., et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8 (2007) 304-310
53. Pre-surgical Detection of Clear Cell Renal Cell Carcinoma Using Radiolabeled G250-Antibody. http://www.clinicaltrials.gov/ct2/show/NCT00606632. Accessed March 9, 2010.
54. Surfus J.E., Hank J.A., Oosterwijk E., et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 19 (1996) 184-191
55. Davis I.D., Wiseman G.A., Lee F.T., et al. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun 7 (2007) 13
56. Bleumer I., Knuth A., Oosterwijk E., et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90 (2004) 985-990
57. Monoclonal Antibody Therapy (Rencarex) in Treating Patients Who Have Undergone Surgery for Non-Metastatic Kidney Cancer. http://www.clinicaltrials.gov/ct2/show/NCT00087022. Accessed March 9, 2010.
58. Liu Z., Smyth F.E., Renner C., Lee F.T., Oosterwijk E., and Scott A.M. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 51 (2002) 171-177
59. Bleumer I., Oosterwijk E., Oosterwijk-Wakka J.C., et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 175 (2006) 57-62
60. Steffens M.G., Boerman O.C., De Mulder P.H., et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 5 Suppl 10 (1999) 3268s-3274s
61. Shih L.B., Thorpe S.R., Griffiths G.L., et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 35 (1994) 899-908
62. Press O.W., Shan D., Howell-Clark J., et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 56 (1996) 2123-2129
63. Sharkey R.M., Behr T.M., Mattes M.J., et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 44 (1997) 179-188
64. Brouwers A.H., van Eerd J.E., Frielink C., et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 45 (2004) 327-337
65. Study of Lutetium-177 Labeled cG250 in Patients With Advanced Renal Cancer. http://www.clinicaltrials.gov/ct2/show/NCT00142415. Accessed March 9, 2010.
66. Divgi C.R., O'Donoghue J.A., Welt S., et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 45 (2004) 1412-1421
67. Vissers J.L., De Vries I.J.M., Schreurs M.W.J., et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 59 (1999) 5554-5559
68. Bleumer I., Tiemessen D.M., Oosterwijk-Wakka J.C., et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 30 (2007) 116-122
69. Uemura H., Fujimoto K., Tanaka M., et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 12 (2006) 1768-1775
70. Tso C.L., Zisman A., Pantuck A., et al. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res 61 (2001) 7925-7933
71. Hernandez J.M., Bui M.H., Han K.R., et al. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin Cancer Res 9 (2003) 1906-1916
72. Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF. http://www.clinicaltrials.gov/ct2/show/NCT00458536. Accessed March 9, 2010.
73. Bauer S., Oosterwijk-Wakka J.C., Adrian N., et al. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Int J Cancer 125 (2009) 115-123
74. Oosterwijk E., Bander N.H., Divgi C.R., et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 11 (1993) 738-750